Yazar "Ozcan, Beyza" seçeneğine göre listele
Listeleniyor 1 - 2 / 2
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Evaluation of the results of pulse oximetry screening for detection congenital heart disease in Konya region, Turkey; Is it cost effective?(2019) Konak, Murat; Ozcan, Beyza; Sert, Ahmet; Uygun, Saime Sundus; Soylu, HanifiAim: Congenital heart disease (CHD) is one of the most common congenital anomalies. It is known that early detection of the critical lesions without symtomatic improves the prognosis of patients in the long term. In our study, we aimed to evaluate the efficacy and cost of pulse oximetry screening for detection of CHD in Konya region.Material and Methods: In our study, we analyzed the results of pulse oximetry screening of infants born between 2016 and 2018 in Selcuk University and Saglik Bilimleri University Konya Training and Research Hospital. Positive screening test results and their costs was evaluated.Results: Pulse oximetry was performed on a total of 3440 infants for screening congenital heart disease at two different centers. 2003 (58.2%) of the cases were female and 1437 (41.8%) were male. The mean timing of screening was 24.7±13.1 (4-100) hours (mean ± SD (min-max). 292 (8.48%) infants were tested positive. Echocardiographic examination was performed in the positive cases. The prevalence of CHD was found to be 27.6 ‰. The prevalence of critical CHD was 1.16 per 1000 live births. The false-positive screen rate was found to be 197 (5.7%). Among the cases who were screened, the most common CHD was the secundum ASD. The total cost of probes was 2622 ₺ ($497.91). The cost of echocardiography for 292 babies was approximately 13181 ₺ ($2503).Conclusion: Screening for heart disease can be used effectively in the early diagnosis of serious and life-threatening diseases in newborn and the cost is unneglectable in the early screening of patients. This study, the total cost of each infant screening is approximately 4.5 ₺ ($0.85) which appears to be a quite cheap and effective screening compared to the other countries.Keywords: Newborn; congenital heart disease; pulse oximetry screening; cardiovascular disease.Öğe Neonatal abstinence syndrome in babies of opioid-addicted mothers and follow-up in the neonatal intensive care unit: A single center experience(2021) Ozcan, BeyzaAim: Neonatal abstinence syndrome (NAS) is a clinical condition characterized by findings that develop after intrauterine exposure to addictive substances, especially opioids, and is characterized by signs related to the absence of the addictive substance in the postpartum period. Typically, NAS manifests in the first few days of life in the form of hypertonia, autonomic instability, irritability, poor absorption reflex, weight loss and, rarely, seizures. The present study was performed the clinical features of mothers who used addictive substances during pregnancy.Materials and Methods: Neonates born between September 2016 and December 2019 to opioid-addicted mothers and admitted to the neonatal intensive care unit (NICU) after birth for findings consistent with NAS were included in this study. The patients' files were analyzed retrospectively. Maternal age, drug used/duration of use, smoking/alcohol use, the last time the substance was taken, gestational week of neonates, mode of delivery, birth weight, onset of NAS symptoms, highest Finnegan score, nutritional status, length of hospitalization, treatment duration and NICU follow-up data were recorded.Results: Nine babies were admitted to the NICU of follow-up for NAS symptoms. All mothers had heroin addiction. The median gestational week of the neonates was 37 (31-40) weeks and median birth weight was 2740(1530-3860) g. Median onset of symptoms was 2(1-4) days and the median Finnegan score of the patients was 10(3-17). Six (66.7%) neonates who did not recover with nonpharmacological treatment received phenobarbital therapy. Conclusions: For patients with NAS, phenobarbital therapy can be used as the first option when symptoms cannot be controlled by nonpharmacological methods in settings such as Turkey where oral morphine solution is not available. In our study, the symptoms were successfully controlled by phenobarbital therapy. However, more comprehensive studies are needed as there are insufficient data on long-term results.